Indivior Pharmaceuticals, Inc. (INDV) Form 10-Q — Oct 29, 2026
Indivior's Q3 2026 net revenue rose 13% to $356 million with net income of $137 million versus $42 million a year ago, driven by 24% U.S. SUBLOCADE growth and gross margin expansion to 86%. The quarter is dominated by the pending all-stock merger with Supernus Pharmaceuticals, approved by both shareholder bases on October 15, 2026 and expected to close on or about November 2, 2026; Indivior holders will own roughly 56.5% of the combined company, which will take the Supernus name with Jack Khattar as CEO.
Key figures
- Eps
- 1.12
- Revenue
- 356
- Net Income
- 137
- Total Debt
- 488
- Total Assets
- 1332
- Cash Position
- 305
- Shares Outstanding
- 118035272
- Exchange Ratio
- 1.5401 Indivior shares per Supernus share
- Gross Margin Q3
- 0.86
- Dental Mdl Cases
- 1925
- Nine Month Revenue
- 1016
- Nine Month Net Income
- 348
- Dental Mdl Plaintiffs
- 22098
- Nine Month Diluted Eps
- 2.78
- Shares Repurchased Ytd
- 8638693
- Special Dividend Total
- 1000000000
- Sublocade Q3 Revenue Us
- 252
- Citi Committed Term Loan
- 650000000
- Share Repurchase Spend Ytd
- 300000000
- Special Dividend Per Share
- 8.13
- Subutex Divestiture Price
- 95000000
- Share Repurchase Remaining
- 100000000
- Convertible Notes Principal
- 500000000
- Share Repurchase Authorized
- 400000000
- Termination Fee Indivior Pays
- 174000000
- Termination Fee Supernus Pays
- 101000000
- Operating Cash Flow Nine Months
- 317000000
- Indivior Ownership Of Combined Co
- 56.5%
- Supernus Ownership Of Combined Co
- 43.5%
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.